AzTrials
AzTrials

Ridge AugmentationNCT06353399

Guided Bone Regeneration With and Without the Use of Intra-marrow Penetrations

A study testing Intra-marrow penetrations and No Intra-marrow penetrations in people with Ridge Augmentation, run by University of Louisville at 2 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The primary aims of this study are to compare, after 6 months, the clinical and histologic results of intra-marrow penetrations vs no intra-marrow penetrations when performing guided bone regeneration procedures. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Ridge Augmentation
What is being tested?
Intra-marrow penetrations and No Intra-marrow penetrations
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
2 sitesUnited States
Study dates
15 Jun 2023to 31 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy male or female who is at least 18 years old.
  • Patients must sign an informed consent approved by the University of Louisville Human Studies Committee.

Who cannot join

  • Patients with debilitating systemic diseases, or diseases that have a clinically significant effect on the periodontium.
  • Presence or history of osteonecrosis of jaws.
  • Patients who are currently taking IV bisphosphonates or who had IV treatment with bisphosphonates irrespective of duration.
  • Patients who have been treated with oral bisphosphonates for more than three years.
  • Patients with an allergy to any material or medication used in the study.
  • Patients who need prophylactic antibiotics
Show all 10Show fewer
  • Previous head and neck radiation therapy.
  • Chemotherapy in the previous 12 months.
  • Patients on long term NSAID or steroid therapy.
  • Pregnant patients.

Trial locations and contacts

2 sites in 1 country.

United States2 sites, 2 recruiting
  • University of Louisville

    Louisville, Kentucky, 40202

    Bindu Dukka, BDS, MSD, MPH, 502- 852- 1817, himabindu.dukka@louisville.edu

    Niti Patel, DMD, 859-685-5423, niti.patel@louisville.edu

    Recruiting
  • University of Louisville

    Louisville, Kentucky, 40202

    Himabindu Dukka, BDS, MSD

    Recruiting

Other trials in United States

About this study

Official title: Guided Bone Regeneration With and Without Use of Intra-marrow Penetrations: A Prospective Human Clinical and Histologic Study

The primary aims of this study are to compare, after 6 months, the clinical and histologic results of intra-marrow penetrations vs no intra-marrow penetrations when performing guided bone regeneration procedures.

Read the detailed description

Study Design Twenty-four patients will be treated using the principles of guided bone generation utilizing full thickness flap for ridge augmentation. Twelve test patients will receive guided bone regeneration with intra-marrow penetrations. The positive control group of twelve patients will receive no intra-marrow penetrations. Approximately, six months post- surgery, a trephine core will be taken from the grafted site immediately prior to implant placement and submitted for histologic processing.

Presurgical Management Each patient will receive a diagnostic work-up including standardized radiographs (periapical), cone beam computed tomography (CBCT) scan, study casts, clinical photographs, and a clinical examination to record attachment level, probing depth, recession, and mobility of teeth adjacent to the extracted sites. Presurgical preparation will include detailed oral hygiene instructions. Baseline data will be collected just before the surgical phase of the treatment.

Clinical Measurements

Baseline and 6-month data will include the following (for edentulous area or adjacent teeth when necessary):

  1. Plaque index
  2. Gingival index
  3. Gingival margin levels: Measured from cemento-enamel junction (CEJ) to the gingival margin.
  4. Keratinized tissue: Measured from the gingival margin to the mucogingival junction.
  5. Clinical attachment level: Measured from CEJ to the bottom of the clinical periodontal pocket.
  6. Clinical tooth mobility: Measured by using the modified Miller's Index.
  7. Ridge dimensions: Pre-augmentation and six month healing.
  8. Soft tissue thickness.
  9. Radiographic examination including CBCT
  10. Clinical photographs.

Histologic Measurements

Measurements will be taken for augmented areas:

Trephine core specimens will be evaluated to determine percent of residual graft particles, newly formed bone, bone marrow, trabecular space, and connective tissue. Step serial sections will be taken from each longitudinally sectioned core. The sections will be stained with hematoxylin and eosin. Ten slides per patients will be prepared with at least 4 sections per slide. For each patient, 6 of 10 slides will be assessed. The mean percentage of vital and nonvital bone, and trabecular space will be determined for each patient by using an American Optical microscope at 150X with 10 X 10 ocular grid.

Potential Risks

There are known physical risks linked with bone graft surgery. The potential risks are the same as the risks of any minor surgery in the mouth. These risks include:

  • Infection of treated area (usually mild, rare less than 1%)
  • Mild bruising and/or bleeding (less likely 1-39%)
  • Mild swelling (more than 40%)
  • Transient but occasional paresthesia or numbness of lips, tongue, chin or gum (usually mild, rare less than 1%)
  • Loss of the bone graft (mild to moderate, rare less than 1%)

There may also be additional risks that are currently unforeseeable.

Adverse Events An "adverse event" refers to any adverse experience occurring during the clinical study period, whether associated or not associated with the study test articles or procedures. A "serious adverse event" means any experiences that suggest significant hazard, contraindication, side effect, or precaution. With respect to human clinical experience, a serious adverse event includes any experience that is fatal or life threatening, causes a persistent or permanent disability, requires initial or prolonged hospitalization, requires medical or surgical intervention to prevent permanent impairment or damage, or is a congenital anomaly.

An "unanticipated adverse event" is one that is not identified in nature, severity, or frequency.

Adverse events will be monitored by observing and interviewing the subject during the study. Subjects who experience any significant problems during the study are to call and discuss them with investigator. Any suspected adverse event or allergic response is to be thoroughly examined by investigator. All adverse events are to be reported. All subjects experiencing adverse events will be followed by the investigator until there is a return to the subject's baseline condition or a clinically satisfactory resolution is achieved. Adverse events that are serious or unanticipated are to be reported immediately by phone to the study director and promptly reported to the institutional review board (IRB), which will include the event date, description of the adverse event, study treatment involved, and outcome of event. Examples of expected, but rarely occurring adverse events related to grafting treatment include clinical observation of infection, flap necrosis, severe inflammation, severe pain, loss of attachment of the gingival tissue to the tooth, reaction to study materials and osteonecrosis.

Measurement Techniques All probing measurements will be taken using the University of North Carolina probe. A masked, calibrated examiner will perform the initial examination and the measurements at the time of initial surgery. The mentor will check these measurements. Differences of more than 1.0 mm between examiners will be remeasured by the blinded examiner. Measurements will again be repeated at the 6-month examination using the same techniques.

Statistical Analysis Means and standard deviations will be calculated for all parameters. A paired t-test will be used to evaluate the statistical significance of the differences between initial and final data. An unpaired t-test will be used to evaluate statistical differences between the test and control groups. The sample size of 12 per group gives _80%__ statistical power to detect a difference of 1 mm between groups. Power calculations were based on data from previous studies.

Research Materials, Records and Privacy The de-identified data collected will be entered in an excel spreadsheet, which will be password protected. The data will be stored in an encrypted computer, which is also password protected. No one will have access to this data other than the individual collecting it and the PI. No personal identifying information will be collected or needed for the study analytical purposes.

Significance The results of this study will allow comparison of the effects of intra-marrow penetrations on guided ridge regeneration in terms of vertical and horizontal dimensions and histologic bone quality.

The Plaque Index The modified O'Leary plaque index (plaque free sites) will be used to obtain dichotomous plaque scores at 6 sites per tooth.

The Gingival Index

The Gingival Index will be measured. Scores will be as follows:

0- Normal Gingiva

  1. Mild inflammation: slight change in color, slight edema
  2. Moderate inflammation: redness, edema, glazing
  3. Severe inflammation: marked redness, edema, and ulceration.

Each gingival unit (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) of the individual tooth will be given a score from 0-3, called the gingival index for the area. The scores from the 6 areas of the tooth are added and divided by 6 to give the gingival index for the tooth.

Standardized Radiographic Technique The Rinn radiographic holder is positioned to allow as near as possible paralleling technique. Radiographs will be taken at baseline and again at 6 months.

Arithmetic Determinations:

  • Change in horizontal ridge dimension: (Pre-op Width) - (Post-op Width).
  • Change in vertical ridge dimension: (Pre-op Distance) - (Post-op Distance)

Tooth mobility 0 - Mobility of the crown is within normal physiologic limits.

  1. Mobility of the crown up to 0.5 mm in one direction. Does not exceed 1.0 mm in both directions.
  2. Mobility of the crown from 0.5 to 1 mm in one direction. Does not exceed 2.0 mm in both directions.
  3. Mobility of the crown exceeding 1 mm in one direction and/or vertical depressibility. Greater than 2.0 mm in both directions and/or vertical depressibility.

Examiner calibration:

The data will be compared from indices or measurements taken by the examiner on three different patients at two different times within a 60-minute period to measure the intra-examiner accuracy and reproducibility.

A minimum of three subjects are to be recruited to participate in the calibration. The subjects should exhibit a range of the criteria being assessed in the index or measurements being performed (i.e., subjects with moderate to severe periodontal disease).

The examiner will score 3 teeth per subject within the same quadrant. The examiner will measure each subject, calling out the measurements, site by site, while the assistant records.

Duplicate measurements of the subjects will be taken within 60 minutes following the initial measurements. The assistant will record the second set of data.

The examiner will not compare the two sets of data at any time during the calibration. The examiner will not discuss their measurements with the assistant or the subject during the calibration.

The assistant recording the data will be responsible for handling the data sheets. The examiner will have no access to any of the data sheets during the course of the calibration.

The data sets will be analyzed for percent agreement. Acceptable percent agreement will reflect the limits set for the different parameters measured.

Acceptable percent agreement will be: 90% within ±1mm for probing depth, recession and attachment level and 70% within 0 mm.

Being tested
Intra-marrow penetrations, No Intra-marrow penetrations

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intra-marrow penetrationsProcedure or surgery

    Intra-marrow penetrations

  • No Intra-marrow penetrationsProcedure or surgery

    No Intra-marrow penetrations

Study groups in NCT06353399
Study groupRoleWhat they receive
Intra-marrow penetrationsExperimentalTwelve test patients will receive guided bone regeneration therapy with the use of intra-marrow penetrations prior to bone graft placement.
Receives: Procedure: Intra-marrow penetrations
No Intra-marrow penetrationsActive comparatorTwelve test patients will receive guided bone regeneration therapy without the use of intra-marrow penetrations prior to bone graft placement.
Receives: Procedure: No Intra-marrow penetrations

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Alveolar Ridge Width

    Alveolar ridge width (measured in mm) after 6 months of healing

    Measured: 6 Months

  2. Alveolar Ridge Height

    Alveolar ridge height (measured in mm) after 6 months of healing

    Measured: 6 Months

  3. Buccal Soft Tissue Thickness

    Buccal soft tissue thickness at crest of alveolar ridge (measured in mm)

    Measured: 6 Months

Secondary outcomes (1)
  1. Histomorphometric Measurements

    Trephine core specimens will be evaluated to determine percent of residual graft, newly formed bone, trabecular space and connective tissue. The sections will be stained with hematoxylin and eosin. The mean percentage of vital and non-vital bone, and trabecular space will be determined for each patient by using an American Optical microscope at 150X with 10 X 10 ocular grid.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Apr 2024
  2. Study start15 Jun 2023
  3. Primary completion30 Jun 2024 (estimated)
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
24 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06353399
Sponsor's protocol ID
23.0366
Status last verified
Apr 2024
First submitted
13 Oct 2023
Last updated
9 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Intra-marrow penetrations and No Intra-marrow penetrations in people with Ridge Augmentation, run by University of Louisville at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Himabindu Dukka, DMD (502-852-1817, himabindu.dukka@louisville.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Alveolar Ridge Width (time frame: 6 Months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in